AnaptysBio logo

AnaptysBio

ANAB | NASDAQ
Chart Builder DCF Calculator
$45.73
-$0.52 (-1.12%)
At close: Nov 16, 2026, 4:00 PM ET
$45.73
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-1.12%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
59.5
-2.0 pts
Fundamentals Strong
Market Sentiment Neutral
Moat Narrow
Sector Rank #136/1021 (Top 13%)

Key Statistics

Market Data

Market Cap $1.36B
1D Range
44.71 46.23
52W Range
23.18 69.81

Valuation (TTM)

PE 9.22
PB 65.30
EV/EBITDA 15.87

Valuation (NTM)

Forward PE 9.72
Forward PEG -0.01
Price Target $79.50
Loading financial charts...

Profile

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Ro...

Sector Healthcare
Industry Biotechnology
Employees 104
IPO Date Jan 26, 2017
Fiscal Year January - December

Latest News

AnaptysBio, Inc. (ANAB) Misses Q3 Earnings and Revenue Estimates

4 days ago · zacks.com

AnaptysBio, Inc. (ANAB) Misses Q3 Earnings and Revenue Estimates
Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

4 days ago · globenewswire.com

Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
Anaptys Announces Participation in Upcoming Investor Conferences

6 days ago · globenewswire.com

Anaptys Announces Participation in Upcoming Investor Conferences
Riverwater Micro Opportunities Strategy Q3 2026 Portfolio Activity

18 days ago · seekingalpha.com

Riverwater Micro Opportunities Strategy Q3 2026 Portfolio Activity
Diamond Hill Small-Mid Cap Fund Q3 2026 Contributors And Detractors

19 days ago · seekingalpha.com

Diamond Hill Small-Mid Cap Fund Q3 2026 Contributors And Detractors
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?

21 days ago · zacks.com

AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?

2 months ago · zacks.com

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

2 months ago · globenewswire.com

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
AnaptysBio: The Royalty Waterfall Is About To Reverse

4 months ago · seekingalpha.com

AnaptysBio: The Royalty Waterfall Is About To Reverse
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?

6 months ago · zacks.com

Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?

Earnings

Latest Earnings
Nov 12, 2026
EPS
$0.11
Beat +105.98%
REV
$30.27M
Beat +18.46%
Next Earnings
Mar 2, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
10
Consensus
Buy
Price Target
$79.50
Upside
+73.85%
Buy (9)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.